Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Mortality Trends in Lymphoid and Hematopoietic Malignancies With Circulatory-System Disease Involvement in the United States, 1999-2024

HL - 825

Mortality Trends in Lymphoid and Hematopoietic Malignancies With Circulatory-System Disease Involvement in the United States, 1999-2024

Madho Mal

Poster Presenter: Madho Mal

Thumbnail for Mortality Trends in Older Adults With Myelodysplastic Syndromes and Cardiovascular Disease: A CDC WONDER Analysis (1999-2025)

MDS - 154

Mortality Trends in Older Adults With Myelodysplastic Syndromes and Cardiovascular Disease: A CDC WONDER Analysis (1999-2025)

Priyanka Keshav Lal

Poster Presenter: Priyanka Keshav Lal

Previous 1...74 75 76 77 78 79 80...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

MM - 1329

Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With First-Line Carfilzomib Versus Bortezomib in Adults With Multiple Myeloma: A Real-World Propensity-Matched Analysis

Chanchal Maheshwari

Poster Presenter: Chanchal Maheshwari

$Thumbnail for Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups$

ABCL - 438

Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups

Jason Westin

Poster Presenter: Jason Westin

Thumbnail for MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

AML - 971

MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

Sai Mourya Meda

Poster Presenter: Sai Mourya Meda

Thumbnail for MRD-Guided Risk Stratification in Venetoclax-Treated Newly Diagnosed AML: A Pooled Survival Analysis

AML - 1351

MRD-Guided Risk Stratification in Venetoclax-Treated Newly Diagnosed AML: A Pooled Survival Analysis

Nuri Tamanna

Poster Presenter: Nuri Tamanna

Thumbnail for MRD-Guided vs Fixed-Duration Targeted Therapy in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Progression-Free Survival and Depth of Response

CLL - 250

MRD-Guided vs Fixed-Duration Targeted Therapy in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Progression-Free Survival and Depth of Response

Sameer Bhimani

Poster Presenter: Sameer Bhimani

Thumbnail for Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

AML - 1483

Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

Paloma Resende

Poster Presenter: Paloma Resende

Thumbnail for Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

MDS - 819

Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

Jeremiah Bearss

Poster Presenter: Jeremiah Bearss

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors